Research and developing medicines to treat diseases are at the cornerstone of what we do.
Collectively, our natural curiosity, our exploration of the unexpected and a patient first attitude allows us to continuously chase the miracles of science.
As one of the top three R&D spenders within the Canadian pharmaceutical and biotechnology industries, and consistently a top spender as a percentage of revenue, we are focused on developing innovative therapies in areas such as oncology, diabetes and cardiology.
As the home of Sanofi’s North American Centres of Excellence for Analytical and Bioprocess R&D, our Toronto site plays an active role in developing new vaccines. Close to 300 people work in R&D at our Toronto site, including dozens of PhDs, Doctors of Pharmacy and bioprocess engineers with extensive academic and/or industry experience.
Homemade slime. Tornado in a bottle.
While simple science activities tap into our desire to explore and experiment, the Sanofi Biogenius Canada Competition takes its up a few notches. And rightly so.
The Sanofi Biogenius Canada Competition encourages high school students from coast-to-coast-to-coast to be curious and explore real-life science, technology, engineering, and mathematics (STEM) research ideas that have the potential change lives.
No ordinary science fair, it annually celebrates outstanding research projects submitted from across the country, from those in Grades 7 to 12, focusing on health sciences, life sciences and biotechnology. Hosted in partnership with Youth Science Canada, the competition is part of their regional and Canada-Wide Science Fair (CWSF).
Three winners are chosen in each of the three divisions: Junior (Grades 7 + 8), Intermediate (Grades 9 and 10) and Senior (Grades 11 + 12).
L-R Sung-In Back, Technologist, and Sahar Esmaeili Samani, Scientist, Vaccine Drug Product Development, Toronto, Canada
Canada has an outstanding reputation for clinical research, built on consistently generating quality data necessary to evaluate a drug’s performance. With over 70 Sanofi-sponsored clinical studies and over 25 investigator-sponsored trials underway in a wide range of therapeutic areas, the Clinical Study Unit in Canada contributes significantly to Sanofi’s global efforts to develop new treatments.
As a health journey partner, we focus on one objective: improving access to healthcare and high-quality medications.
In addition to providing medications in a wide range of therapeutic areas, Sanofi Canada also offers a number of patient-focused programs designed to help people better manage their health and secure access to the treatments they need.
Where permitted, a free prescription savings card available to all Canadian residents, whether or not they have an existing drug plan
For patients prescribed Renagel® or Renvela®. Includes drug benefit assistance and financial assistance.
For patients prescribed SYNVISC®/Synvisc-One® for osteoarthritis of the knee, hip, shoulder & ankle. Supports a multimodal treatment approach.
A dedicated support program for people with multiple sclerosis, their care partners, and healthcare professionals. To learn more, call 855.671.2663.
For patients prescribed KEVZARA®, providing injection training and follow-up, home delivery and reimbursement assistance.
Patients prescribed Praluent® may have access to the following program services: product administration training, treatment reminders, reimbursement navigation, copay assistance and a toll-free call center. To contact MyPraluent Coach™, please call 1-866-772-5836.
Canada has an outstanding reputation for clinical research, built on consistently generating quality data necessary to evaluate a drug’s performance. The high level of medical expertise in Canada and the openness of investigative centres to clinical development make Canada attractive for Sanofi’s clinical research operations.
The Clinical Study Unit in Canada contributes significantly to Sanofi’s global efforts to develop new treatments. Our teams are currently overseeing some 70 Sanofi-sponsored clinical studies in a wide range of therapeutic areas, working with clinics and hospitals across the country.
Clinical studies are crucial in determining whether a particular drug is safe and effective, at which dosage, and any potential side effects. Only with all these data can regulatory approval (Health Canada’s “Notice of Compliance”) be obtained and the medicine made available to patients. Once a medicine is on the market, additional studies may be performed to learn more about its effectiveness and safety in various patient groups.
